Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status

Leukemia. 2005 Feb;19(2):287-9. doi: 10.1038/sj.leu.2403584.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Blast Crisis / drug therapy
  • Blast Crisis / genetics*
  • Catalytic Domain
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Piperazines / therapeutic use*
  • Proto-Oncogene Proteins c-abl / genetics*
  • Pyrimidines / therapeutic use*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sequence Deletion
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-abl